Is Cabaletta Bio going out of business?

CABALETTA BIO, INC. (CABA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

CABALETTA BIO, INC. (CABA) scores 18 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 133.76% (YoY)

Five questions, kept separate

Survival - Funding dependent

17-24 mo of estimated runway from 2026-06-30, based on $225M of cash and short-term investments against $132M of annual burn. Adjusted shares outstanding increased 133.8% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

16.1% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 133.76% (YoY)
• Debt / Equity: -0.95x (Net Cash)
• ROIC: -1118.77%
• Interest coverage: -80.9x
• Return on Assets: -65.38%
• Cash Runway (years): 1.70y
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-13.

Price as of 2026-09-07.